Oragenics Inc. (NYSE American: OGEN) announced that all three sites in its Australian Phase IIa clinical trial of ONP-002 for mild traumatic brain injury (concussion) are now active and enrolling participants, following the activation of Royal Adelaide Hospital. The company reported that no serious adverse events have been observed in dosed participants to date, and it continues to target a Phase IIa data readout in the fourth quarter of 2026.
In addition, Oragenics submitted a Type B meeting request to the U.S. Food and Drug Administration on June 26 to obtain guidance on its planned U.S. clinical development program for ONP-002. The company stated that this meeting supports its goal of submitting an Investigational New Drug application in the fourth quarter of 2026.
ONP-002 is being developed as a potential first-in-class treatment for concussion and mild traumatic brain injury, delivered via Oragenics' proprietary intranasal delivery technology. The company believes this platform has potential applications across multiple neurological conditions, including Parkinson's disease, Alzheimer's disease, PTSD, and anxiety disorders.
The activation of all trial sites in Australia marks a significant step forward for the clinical program. With enrollment now underway, the company is gathering safety and efficacy data that will inform future trials. The absence of serious adverse events is a positive early signal for the drug's safety profile.
The FDA meeting request indicates Oragenics is proactively seeking regulatory feedback to align its development strategy with U.S. requirements. A successful meeting could streamline the path to U.S. clinical trials, potentially accelerating the timeline for bringing ONP-002 to market. The company aims to address a significant unmet medical need, as current treatment options for concussion are limited.
For investors, these developments underscore Oragenics' commitment to advancing its pipeline and its strategic approach to regulatory engagement. The company's progress in Australia provides a foundation for broader clinical development. More information can be found in the full press release at https://ibn.fm/Yye2E.
Oragenics is a clinical-stage biotechnology company focused on developing brain-targeted therapeutics. For further details, visit oragenics.com.
